Insulin Initiation and Titration in Type 2 Diabetes
|
|
- Samuel Brooks
- 7 years ago
- Views:
Transcription
1 Learning Objectives Insulin Initiation and Titration in Type 2 Diabetes Toronto East General Hospital Drugs & Therapeutics Update April 24, By the end of this session, participants will be able to: 1. Understand the different types of insulin, dosing regimens, and principles in the management of type 2 DM; and 2. Apply this knowledge to the initiation and titration of insulin in clinical practice. Jim Jim 54 yo M T2DM x 10 yrs HTN, hyperlipidemia Chronic knee pain Smoker, occ. EtOH Depression Limited exercise, irregular meals Married, 2 step children, stress ++, conflict ODSP metformin 1 g BID sitagliptin (Januvia) 100 mg OD glyburide 5 mg BID other meds for lipids, HTN, depression, chronic pain FBS 11.7 HbA1C 9.1% egfr 110 BMI 32 Now what? Increase the dose of metformin +/- glyburide? Add another hypoglycemic agent? Encourage greater lifestyle modification? Start insulin? Refer to Endo? Refer to your local DEP/DEC? Victor 59 years old FBS 6.7 mmol/l A1C 6.2% Does he have diabetes?
2 Diagnosis of Diabetes FPG 7.0 mmol/l Fasting = no caloric intake for at least 8 hours or A1C 6.5% (in adults) Using a standardized, validated assay, in the absence of factors that affect the accuracy of the A1C and not for suspected type 1 diabetes or 2hPG in a 75-g OGTT 11.1 mmol/l or Random PG 11.1 mmol/l Random= any time of the day, without regard to the interval since the last meal Diagnosis of Prediabetes* Test Result Prediabetes Category Fasting Plasma Glucose (mmol/l) 2-hr Plasma Glucose in a 75-g Oral Glucose Tolerance Test (mmol/l) Glycated Hemoglobin (A1C) (%) Impaired fasting glucose (IFG) Impaired glucose tolerance (IGT) Prediabetes * Prediabetes = IFG, IGT or A1C % high risk of developing T2DM 2hPG = 2-hour plasma glucose; FPG = fasting plasma glucose; OGTT = oral glucose tolerance test; PG = plasma glucose VICTOR Lost to follow up and shows up 3 years later FBS 9.0 mmol/l A1C 8.3% Targets Checklist A1C 7.0% for MOST people with diabetes A1C 6.5% for SOME people with T2DM A1C % in people with specific features What are the A1C targets for Victor? Individualizing A1C Targets Consider % if: What do you prescribe for his glucose control? which must be balanced against the risk of hypoglycemia
3 Pharmacotherapy in T2DM Checklist CHOOSE initial therapy based on glycemia START with Metformin +/- others INDIVIDUALIZE your therapy choice based on characteristics of the patient and the agent REH TARGET within 3-6 months of diagnosis GET TO TARGET WITHIN 3-6 MONTHS OF DIAGNOSIS Initial Choice of Therapy Depends on Glycemia Initial A1C <8.5% Start metformin OR Reassess in 2-3 months then decide on starting metformin Initial Choice of Therapy Depends on Glycemia Symptomatic Polyuria Hyperglycemia Polydipsia + Weight loss Metabolic Volume depletion Decompensation Initial A1C 8.5% Start metformin AND Consider combo therapy to achieve 1.5% A1C reduction Concern about Insulin Deficiency INSULIN +/- Metformin What Comes After Metformin? Depends Patient characteristics Degree of hyperglycemia Risk of hypoglycemia Weight Comorbidities (renal, cardiac, hepatic) Access to treatment Agent characteristics BG lowering efficacy & durability Risk of inducing hypoglycemia Effect on weight Contraindications & side effects Cost and coverage Patient preferences Other
4 What are the Barriers to Insulin Therapy? Resistance to Insulin Therapy Patient Low perceived clinical efficacy High self-blame/ failure Negative history, perceived harm Fear of needles Permanence/Restrictivenes s Weight gain, hypoglycemia Provider Wait until absolute necessity Reluctance/delay to use OHAs Low perceived clinical efficacy Use of strategy: insulin = poor self-management Perception of patients Lack of knowledge/experience Lack of time, support Insulin Insulin Manufactured insulin is designed to mimic the properties of endogenous insulin Properly dosed low risk Greatest potential reduction in A1C Hypoglycemia most frequent AE but not common Weight gain may occur Allergic reactions rare When to start? How to choose insulin type and regimen? How to dose? What to do with the oral agents? Insulin in T2DM: When to Start? Insulin in T2DM: The Rule of 3 s At any point when glycemic control is inadequate (KEY POINT) Metabolic decompensation End-organ failure Pregnant or planning pregnancy Temporarily for acute illness, stress or medical procedure/surgery 3 insulin categories 3 insulin regimens 3 insulin dosing principles Alice Cheng, 2011
5 Insulin in T2DM: 3 Categories Types of Insulin Insulin Type (trade name) Onset Peak Duration 1. Basal 2. Bolus (meal time) 3. Premixed Bolus (prandial) Insulins Rapid-acting insulin analogues (clear): Insulin aspart (NovoRapid ) Insulin glulisine (Apidra ) Insulin lispro (Humalog ) Short-acting insulins (clear): Insulin regular (Humulin -R) Insulin regular (Novolin getoronto) Basal Insulins Intermediate-acting insulins (cloudy): Insulin NPH (Humulin -N) Insulin NPH (Novolin ge NPH) Long-acting basal insulin analogues (clear) Insulin detemir (Levemir ) Insulin glargine (Lantus ) min min min h h 1-2 h 3-5 h 3-5 h h 30 min 2-3 h 6.5 h 1-3 h 5-8 h Up to 18 h 90 min Not applicable Up to 24 h (glargine 24 h, detemir h) Types of Insulin (continued) Insulin in T2DM: 3 Regimens Insulin Type (trade name) Premixed Insulins Premixed regular insulin NPH (cloudy): 30% insulin regular/ 70% insulin NPH (Humulin 30/70) 30% insulin regular/ 70% insulin NPH (Novolin ge 30/70) 40% insulin regular/ 60% insulin NPH (Novolin ge 40/60) 50% insulin regular/ 50% insulin NPH (Novolin ge 50/50) Premixed insulin analogues (cloudy): 30% Insulin aspart/70% insulin aspart protamine crystals (NovoMix 30) 25% insulin lispro / 75% insulin lispro protamine (Humalog Mix25 ) 50% insulin lispro / 50% insulin lispro protamine (Humalog Mix50 ) Time action profile A single vial or cartridge contains a fixed ratio of insulin (% of rapid-acting or short-acting insulin to % of intermediate-acting insulin) 1. Basal insulin once daily 2. Basal + bolus insulin 3. Premixed insulin twice daily Serum Insulin Level Serum Insulin Level Time Human Basal: Humulin-N, Novolin ge NPH Human Bolus: Humulin-R, Novolin ge Toronto Analogue Basal: Lantus, Levemir Analogue Bolus: Apidra, Humalog, NovoRapid Time Human Premixed: Humulin 30/70, Novolin ge 30/70 Analogue Premixed: Humalog Mix25, NovoMix 30
6 Insulin in T2DM: 3 Dosing Principles 1. Whatever starting dose you select will be wrong 2.Titration is key to success 3.There is no maximum dose of insulin Jim Start Insulin? Jim 4 Weeks Later 54 yo M T2DM x 10 yrs HTN, hyperlipidemia Chronic knee pain Smoker, occ. EtOH Depression Limited exercise, irregular meals Married, 2 step children, stress ++, conflict ODSP metformin 1 g BID sitagliptin (Januvia) 100 mg OD glyburide 5 mg BID Other meds for lipids, HTN, depression, chronic pain FBS 11.7 HbA1C 9.1% egfr 110 BMI 32 Date Breakfast Lunch Supper Bedtime Sun Mon Tues Wed Thurs Fri Sat You refer Jim to your local DEP where he is provided with a meter and teaching re SMBG The DEP providers have explored initiating insulin and he presents with his logbook and a readiness to start What will you do? Basal Insulin Once Daily To achieve A1C 7.0% Start at 10 U at bedtime A1C (%) Preprandial PG (mmol/l) 2-h postprandial PG (mmol/l) Increase by 1 U every night until target FBS achieved Most will require U (but remember no max dose!) Reduce the dose if any hypoglycemia For most patients (5-8 if A1C not at target)
7 Jim Another 4 Weeks Later Jim Yet Another 4 Weeks Later Date Breakfast Lunch Supper Bedtime Sun Mon Tues Wed Thurs Fri Sat Jim has been titrating his glargine (Lantus) as directed He s now at 34 U at bedtime He reports feeling lightheaded & dizzy in the afternoon Jim presents to your office for follow up He has experienced no further lows since stopping the glyburide and generally is feeling better overall He has stopped titrating up because he hit 50 U Day Breakfast Sunday 6.4 Monday 7.3 Tuesday 6.8 Wednesday 7.9 Thursday 7.6 Friday 6.9 Saturday 8.7 Jim 2 Years Later Jim 2 Years Later 56 yo M BS have been well controlled until recently Tries hard to make lifestyle modifications but is continuing to struggle with a chaotic schedule metformin 1 g BID sitagliptin (Januvia) 100 mg OD glargine (Lantus) 55 U at QHS HbA1C 8.1% egfr 97 BMI 32 Date Breakfast Lunch Supper Bedtime Sunday Monday Tuesday Wednesday Thursday Friday Saturday Basal + Bolus Insulin Bolus = Start with 2-4 U Titrate targeting 2 hr PC BS or next meal/hs Stop all OHAs except metformin Basal + Bolus Insulin If insulin naïve then: TDI = 0.5 U/kg 40% TDI = basal dose 60% TDI = bolus dose (divided into 3 meals) Titrate basal to FBS and bolus to either 2 hr PC BS or BS next meal Example 70 kg M TDI = 0.5 U/kg x 70 kg = 35 U Dosing regimen: 40% x 35 U = 14 U basal insulin at HS 60% x 35 U/3 meals = 7 U /@ meals
8 Nancy Nancy 3 weeks later 55 yo F New pt to practice T2DM x 12 yrs, started on insulin 1 yr ago HTN, hyperlipidemia, GERD Smokes, no EtOH Works PT, stressful job, married, 3 children Metformin 1 g BID gliclazide modified release (Diamicron MR) 120 mg OD NPH 22 HS FBS 11.2 HbA1C 8.4% egfr 102 Unscheduled follow up appointment Nancy has been titrating her NPH as per instructions and is now at 36 U HS She reports that her FBS have been running high recently (after initially improving) and notes that she is feeling more tired, less well overall FBS 11.3 Now what? Nancy 15 months later Nancy 15 months later NPH reduced to 28 U and she gradually has titrated upward and is now at 32 U FBS have normalized, and HbA1C was <7% at 6 months follow up But now her A1C is rising again and FBS remain normal Date Breakfast PC Breakfast PC Lunch PC Supper Monday Tuesday Wednesday Thursday Friday Saturday Sunday 11.8 Premixed Insulin Twice Daily To achieve A1C 7.0% Start at a dose of 5-10 U twice daily A1C (%) Preprandial PG (mmol/l) 2-h postprandial PG (mmol/l) Titrate breakfast dose to supper BS 4-7 Titrate supper dose to next day FBS 4-7 Safe to increase by 1 U/day For most patients (5-8 if A1C not at target)
9 Nancy One Year Later Nancy Two Years Later Now 57 yo F Started on a premixed analogue now at 22 U at breakfast and 14 U at supper metformin 1 g BID A1C 6.7% FBS 6.2 Date Breakfast Lunch Supper Bedtime Sunday Monday Tuesday Wednesday Thursday Friday Saturday George George 75 yo M T2DM x 20 yrs Meds: Metformin 1000 mg BID, glyburide 10 mg BID, sitagliptin 100 mg PO OD HbA1C 9% Wt 80 kg Options: Start basal insulin? Start mixed insulin? And what about the OHAs? Option #1 Start basal insulin at HS and titrate by 1 U daily until FBS 4-7 Start at 10 U Cont. metformin +/- sitagliptin D/C glyburide b/c risk of hypoglycemia Option #2 Start 5-10 U mixed insulin breakfast and supper Titrate to supper BS 4-7 and next day FBS 4-7 Cont. metformin, D/C glyburide + sitagliptin George Diabetes in the Elderly Checklist On pre-mixed (30/70) 25 U AM, 15 U supper HbA1C 7.8% Experiencing lows 2 hrs. after breakfast, corrects with orange juice Breakfast Lunch Supper What s the pattern? Highs/lows? What decision re insulin? Bedtime ASSESS for level of functional dependency (frailty) INDIVIDUALIZE glycemic targets based on the above (A1C 8.5% for frail elderly) but if otherwise healthy, use the same targets as younger people AVOID hypoglycemia in cognitive impairment SELECT antihyperglycemic therapy carefully Caution with sulfonylureas or thiazolidinediones Basal analogues instead of NPH or human 30/70 insulin Premixed insulins instead of mixing insulins separately GIVE regular diets instead of diabetic diets or nutritional formulas in nursing homes
10 Among Frail Elderly Parameter A1C FPG or preprandial glucose FPG= Fasting Plasma Glucose Target 8.5% mmol/l (depending on level of frailty) AVOID HYPOGLYCEMIA Add an agent best suited to the individual (agents listed in alphabetical order): Class Relative A1C Lowering Hypoglycemia Weight Other therapeutic considerations Cost glucosidase inhibitor (acarbose) Incretin agents: DPP 4 Inhibitors GLP 1 receptor agonists Rare Neutral to Improved postprandial control, GI side effects Rare N to May use detemir or glargine instead $$$ of to Rare GI side effects NPH or human 30/70 for less hypos $$$$ Premixed insulins and prefilled insulin pens instead of mixing insulin to Insulin Yes No dose reduce ceiling, dosing flexible errors regimens $ $$$$ Insulin secretagogue: *Less CAUTION hypoglycemia in the in elderly context of Meglitinide Yes* missed Initial meals doses but = usually HALF requires of usual dose $$ Sulfonylurea Yes TID Avoid to QID glyburide dosing $ Gliclazide Use gliclazide, and glimepiride gliclazide associated MR, with glimepiride, less hypoglycemia nateglinide than or repaglinide glyburide instead Thiazolidinediones Rare CHF, CAUTION edema, fractures, in the elderly rare bladder $$ cancer Increased (pioglitazone), risk of cardiovascular fractures controversy Increased (rosiglitazone), risk of heart 6 12 failure weeks required for maximal effect Weight loss agent (orlistat) None GI side effects $$$ $$ Diabetes Education Programs Education and support for people with T2DM, prediabetes and at risk Self-management support, incl. motivational interviewing, goal setting and action planning Medication support/consultation Insulin initiation and titration +/- ordering DM labs (A1C) **** Care coordination **** Staffed by RN and RD, generally CDE Community based Summary Counsel all Patients About Sick Day Medication List Insulin is safe and effective in the management of type 2 DM Most important step is titration and not the starting dose Use the rule of 3 s to guide its use Use your local DEP Be aware of your own resistance
A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationApproximate Cost Reference List i for Antihyperglycemic Agents
Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationTherapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationTYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic.
TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD www.diabetesclinic.ca Author: Dr. Robin Conway Note to readers The contents herein represent
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More information(30251) Insulin SQ Prandial Carbohydrate
Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered
More informationLet s Talk About Meters and Meds. Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014
Let s Talk About Meters and Meds Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014 How to monitor diabetes control: Hemoglobin A 1 C, or just A 1
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationGuidelines for Type 2 Diabetes Diagnosis
Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose
More informationTREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS. Friday, August 16, 13
TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS 1 Heather Healy, FNP-BC Martha Shelver, CS, ACNP-BC Saint Alphonsus Regional Medical Center 2 OBJECTIVES 3 Review the current management algorithms
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationDiabetes Treatments: Options for Insulin Delivery. Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute
Diabetes Treatments: Options for Insulin Delivery Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Diabetes 21 million people in the U.S. have diabetes $132 billion each
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationCara Liday, PharmD, CDE Associate Professor, Idaho State University Clinical Pharmacist and CDE, InterMountain Medical Center Pocatello, ID The planners and presenter have disclosed no conflict of interest,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationInsulin use in Type 2 Diabetes. Dr Rick Cutfield. Why? When? How?
Insulin use in Type 2 Diabetes Dr Rick Cutfield Why? When? How? 1 Conflict of Interest I have been on advisory boards or had speaker fees from the following pharmaceutical companies: - Eli Lilly - Novo
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationDiabetes DIABETES MELLITUS. Types of Diabetes. Classification of Diabetes 6. 10. 2013. Prediabetes: IFG, IGT, Increased A1C
Diabetes Diabetes mellitus is a chronic disease characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. A state of raised blood glucose (hyperglycaemia)
More information10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama
Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationSUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS
SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS PURPOSE To establish a process that will enable Certified Diabetes Educators (CDE) and/or staff with Board Certification in Advanced Diabetes Management
More informationMaking Clinical Sense of Diabetes Medications. Types of Diabetes. Pathophysiology. Beta Cell Function & Glucagon
Making Clinical Sense of Diabetes Medications Kathy Reily, RD, CDE Prince William Hospital Diabetes Program Coordinator Virginia Dietetic Association April 4, 2011 Types of Diabetes Type 1 DM = Beta Cell
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationOnset Peak Duration Comments
Rapid- Acting 5-15 minutes 0.5-3 hours 3-5 hours Meal should be available before administering, ideally taking within 10 minutes of eating). Good in refrigerator (36-46 F) until expiration date. Protect
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationAntidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
More informationThe Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT
Welcome! Thank you for joining the webinar: The Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT The webinar will begin shortly.
More informationManaging the Hospitalized Patient on Insulin: Care Transition. Catie Prinzing MSN, APRN, CNS
Managing the Hospitalized Patient on Insulin: Care Transition Catie Prinzing MSN, APRN, CNS Diabetes and Hospitalization People with DM are hospitalized 3x more frequently than patients without diabetes
More informationINSULINThere are. T y p e 1 T y p e 2. many different insulins for
T y p e 1 T y p e 2 INSULINThere are many different insulins for Characteristics The three characteristics of insulin are: Onset. The length of time before insulin reaches the bloodstream and begins lowering
More information10 to 30 minutes ½ to 3 hours 3 to 5 hours. 30 60 minutes 1 to 5 hours 8 hours. 1 to 4 hours
Insulin Action There are several types of insulin. They are classified by how long they act: very fast, fast, slow and very slow acting. Each type of insulin has a certain time period in which it works.
More informationCase Studies: Initiation and Optimization of Insulin Therapy. Martha Nolte Kennedy, MD UCSF March, 2009
Case Studies: Initiation and Optimization of Insulin Therapy Martha Nolte Kennedy, MD UCSF March, 2009 When to Start Insulin? Insulinopenia: DM1, LADA, DM2 failed other medications, s/p Pancreatectomy,
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationAbdulaziz Al-Subaie. Anfal Al-Shalwi
Abdulaziz Al-Subaie Anfal Al-Shalwi Introduction what is diabetes mellitus? A chronic metabolic disorder characterized by high blood glucose level caused by insulin deficiency and sometimes accompanied
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationDiabetes Medications. Minal Patel, PharmD, BCPS
Diabetes Medications Minal Patel, PharmD, BCPS Objectives Examine advantages and disadvantages of oral anti-hyperglycemic medications Describe the differences between different classes of insulin Explore
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationEndocrine Disorders. Diabetes Meds Objectives. Diabetes Type 1 and Type 2. Insulin Dynamics. Insulin is all about timing! Rapid acting insulin O P D
Endocrine Disorders Diabetes Meds Objectives Explain the action of the various types of insulin currently available Identify the relationship between insulin peak and risk for hypoglycemia Discuss rationale
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationInsulin T Y P E 1 T Y P E 2
T Y P E 1 T Y P E 2 INSULIN There are many different insulins for many different situations and lifestyles. This section should help you and your doctor decide which insulin or insulins are best for you.
More informationAnti-Diabetic Agents. Chapter. Charles Ruchalski, PharmD, BCPS. Drug Class: Biguanides. Introduction. Metformin
Chapter Anti-Diabetic Agents 2 Charles Ruchalski, PharmD, BCPS Drug Class: Biguanides The biguanide metformin is the drug of choice as initial therapy for a newly diagnosed patient with type 2 diabetes
More informationStarting or Changing Insulin Therapy For the Generalist Physician
Starting or Changing Insulin Therapy For the Generalist Physician SGIM National Meeting 2008 DC Dugdale, MD, FACP Division of GIM, University of Washington Dawn E. DeWitt MD, FACP, FRACP University of
More informationDiabetes Update Lanita S. Shaverd, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor, UAMS College of Pharmacy
Objectives Review oral medications used for the treatment of diabetes Explain how to effectively combine oral diabetes medications for optimal results Discuss insulins and non-insulin injectable diabetes
More informationTreating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document
Treating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document Disclaimer: This document is offered as a service to New York State Prescribers to inform about the most current
More informationFYI: (Acceptable range for blood glucose usually 70-110 mg/dl. know your institutions policy.)
How Insulin Works: Each type of insulin has an onset, a peak, and a duration time. Onset is the length of time before insulin reaches the bloodstream and begins lowering blood Peak is the time during which
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationDIABETES CARE PROGRAM OF NOVA SCOTIA INSULIN DOSE ADJUSTMENT POLICIES & GUIDELINES MANUAL, 2012
DIABETES CARE PROGRAM OF NOVA SCOTIA INSULIN DOSE ADJUSTMENT POLICIES & GUIDELINES MANUAL, 2012 Published by: Diabetes Care Program of Nova Scotia 1276 South Park Street, Bethune Building, Room 548 Halifax,
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationType 2 Diabetes in Children
Type 2 Diabetes in Children February 19, 2005 Brandon Nathan, MD Endocrinology Department of Pediatrics University of Minnesota Medical School University of Minnesota Masonic Children s Hospital Agenda
More informationDr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationInsulin pen start checklist
Insulin pen start checklist Topic Instruction Date & Initials 1. Cognitive Assessment 2. Insulin Delivery loading appropriate mixing priming shot dialing up dose delivery of insulin 3. Insulin type/action
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More informationDiabetes: Medications
Diabetes: Medications Presented by: APS Healthcare Southwestern PA Health Care Quality Unit (APS HCQU) May 2008 sh Disclaimer Information or education provided by the HCQU is not intended to replace medical
More informationStarting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres
Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having bowel preparation for a flexible sigmoidoscopy or a colonoscopy or a combined gastroscopy and colonoscopy This guidance is provided to assist
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow
More informationLeicestershire Diabetes Guidelines: Insulin Therapy
Endorsed by Leicestershire Medicines Strategy Group Leicestershire Diabetes Guidelines: Insulin Therapy These guidelines are designed for use by those trained and competent in insulin initiation and management
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationMANAGEMENT OF TYPE - 1 DIABETES MELLITUS
MANAGEMENT OF TYPE - 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationDonovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center. U-500 Insulin
Donovan Victorine Pharm.D. BCACP Clinical Pharmacy Specialist Boise VA Medical Center U-500 Insulin Understand differences between U-500 concentrated insulin and standard insulin formulations Recognize
More informationComparative cardiovascular morbidity and mortality in patients taking different insulin regimes for type 2 diabetes: A systematic review
Comparative cardiovascular morbidity and mortality in patients taking different insulin regimes for type 2 diabetes: A systematic review Search Question: What is the impact of insulin type, does and regime
More information